Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review.
Izcovich A, Ragusa MA, Tortosa F, Lavena Marzio MA, Agnoletti C, Bengolea A, Ceirano A, Espinosa F, Saavedra E, Sanguine V, Tassara A, Cid C, Catalano HN, Agarwal A, Foroutan F, Rada G. · 2020
Read Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. by Izcovich A, Ragusa MA, Tortosa F, Lavena Marzio MA, Agnoletti C, Bengolea A, Ceirano A, Espinosa F, Saavedra E, Sanguine V, Tassara A, Cid C, Catalano HN, Agarwal A, Foroutan F, Rada G. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7671522.txt.
Introduction
Izcovich and co-authors hunt for traits that predict severe COVID-19 or death. Clinicians need such signs to sort care for infected patients. The team searched major databases through April 28, 2020. They set no limits on study type or language.
The review took in 207 studies. It found 49 factors with high or moderate certainty of value. They span age and sex, past illness, signs on exam, and lab results. High blood markers of inflammation and organ strain stood out, as did low lymphocyte counts. The authors grade the strength of proof for each factor to guide bedside use.
Catalog record
| CREATOR | Izcovich A, Ragusa MA, Tortosa F, Lavena Marzio MA, Agnoletti C, Bengolea A, Ceirano A, Espinosa F, Saavedra E, Sanguine V, Tassara A, Cid C, Catalano HN, Agarwal A, Foroutan F, Rada G. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 89 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review By Ariel Izcovich, Martín Alberto Ragusa, Fernando Tortosa, María Andrea Lavena Marzio, Camila Agnoletti, Agustín Bengolea, Agustina Ceirano, Federico Espinosa, Ezequiel Saavedra, Verónica Sanguine, Alfredo Tassara, Candelaria Cid Published in: PLoS ONE DOI: 10.1371/journal.pone.0241955 ABSTRACT Background and purpose The objective of our systematic review is to identify prognostic factors that may be used in decision-making related to the care of patients infected with COVID-19. Data sources We conducted highly sensitive searches in PubMed/MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL) and Embase. The searches covered the period from the inception date of each database until April 28, 2020. No study design, publication status or language restriction were applied. Study selection and data extraction We included studies that assessed patients with confirmed or suspected SARS-CoV-2 infectious disease and examined one or more prognostic factors for mortality or disease severity. Reviewers working in pairs independently screened studies for eligibility, extracted data and assessed the risk of bias. We performed meta-analyses and used GRADE to assess the certainty of the evidence for each prognostic factor and outcome. Results We included 207 studies and found high or moderate certainty that the following 49 variables provide valuable prognostic information on mortality and/or severe disease in patients with COVID-19 infectious disease: Demographic factors (age, male sex, smoking), patient history factors (comorbidities, cerebrovascular disease, chronic obstructive pulmonary disease, chronic kidney disease, cardiovascular disease, cardiac arrhythmia, arterial hypertension, diabetes, dementia, cancer and dyslipidemia), physical examination factors (respiratory failure, low blood pressure, hypoxemia, tachycardia, dyspnea, anorexia, tachypnea, haemoptysis, abdominal pain, fatigue, fever and myalgia or arthralgia), laboratory factors (high blood procalcitonin, myocardial injury markers, high blood White Blood Cell count (WBC), high blood lactate, low blood platelet count, plasma creatinine increase, high blood D-dimer, high blood lactate dehydrogenase (LDH), high blood C-reactive protein (CRP), decrease in lymphocyte count, high blood aspartate aminotransferase (AST), decrease in blood albumin, high blood interleukin-6 (IL-6), high blood neutrophil count, high blood B-type natriuretic peptide (BNP), high blood urea nitrogen (BUN), high blood creatine kinase (CK), high blood bilirubin and high erythrocyte sedimentation rate (ESR)), radiological factors (consolidative infiltrate and pleural effusion) and high SOFA score (sequential organ failure assessment score). Conclusion Identified prognostic factors can help clinicians and policy makers in tailoring management strategies for patients with COVID-19 infectious disease while researchers can utilise our findings to develop multivariable prognostic models that could eventually facilitate decision-making and improve patient important outcomes. Systematic review registration Prospero registration number: CRD42020178802. Protocol available at: https://www.medrxiv.org/content/10.1101/2020.04.08.20056598v1. INTRODUCTION COVID-19 is an infectious disease caused by the SARS-CoV-2 coronavirus [1]. It was first identified in Wuhan, China, on December 31, 2019 [2]; five months later, more than six million cases had been identified across 215 countries [3]. On March 11, 2020, WHO characterised the COVID-19 outbreak as a pandemic [1]. While the majority of cases present with mild symptoms, a minority progress to acute respiratory illness and hypoxia requiring hospitalization, and a subset develop acute respiratory distress syndrome, multi-organ failure or have fatal outcomes [4]. The case fatality rate reported across countries, settings and age groups is highly variable, ranging from about 0.5% to 10% [5]. In hospitalised patients it has been reported to be higher than 20% [6]. Prognostic factors (stand-alone or combined in risk assessment models) may guide the stratification of patients with SARS-CoV-2 infectious disease based on their risk of severe disease or death. This risk stratification may subsequently guide optimised management and resource utilisation strategies in the care of these patients. Although multiple prognostic factors have been proposed and some have been accepted as “established” by the scientific community (i.e age), the predictive value of most of these potential prognostic factors has not been robustly evaluated and remains uncertain. As pointed out by Wynants et.al: “unreliable predictors could cause more harm than benefit in guiding clinical decisions” [7]. For example, aggressive and risky interventions might be attempted if the risk of poor outcomes are inaccurately defined as high based on unreliable predictors. Using innovative and agile processes supported by advanced evidence synthesis tools and collaborative efforts across several international research groups, this systematic review aims to provide a rigorous summary of the evidence available on prognostic factors that may be used in decision-making related to the care of patients infected with COVID-19. METHODS Protocol registration We published [8] and registered the protocol for this systematic review with PROSPERO (CRD42020178802). Search strategy We conducted highly sensitive searches in PubMed/MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL) and Embase. The searches covered the period from the inception date of each database until April 28, 2020. No study design, publication status or language restriction were applied. Detailed strategies for each database are reported in the S1 Text. In order to identify articles that might have been missed in the electronic searches, we reviewed the reference list of each included study and performed cross citation in Google Scholar using each included study as the index reference. Study selection Four reviewers working independently and in duplicate, performed study selection, including screening of titles and abstracts and of potentially eligible full-text articles. Reviewers resolved disagreements by discussion. We included studies examining individual prognostic factors or risk assessment models based on the typologies of prognosis proposed by Iorio and colleagues [9] and the PROGnosis RESearch Strategy (PROGRESS) Group framework [10] without applying any restrictions based on analytical methods (i.e performing multivariable analysis). Specifically, we included studies that evaluated patients with confirmed SARS-CoV-2 infectious disease regardless of the healthcare setting (i.e ambulatory or inpatients) and of baseline disease severity. We investigated all candidate prognostic factors reported by individual studies and compared patients exposed (the factor was present) with patients unexposed (the factor was absent) to each one of those factors.We considered studies that assessed mortality or severe COVID-19 disease as outcomes and accepted the author's definitions of the latter. When severe COVID-19 disease was reported as a multi-categorical scale, we used the most severe category. Additionally, when severe COVID-19 disease was not reported as an outcome, we considered ICU requirement, invasive mechanical ventilation (IVM) and acute respiratory distress syndrome (ARDS) as surrogate outcomes. Data extraction For each eligible study, five pairs of reviewers, independently, abstracted the following information on study characteristics (year of publication, country, medical center and time period in which the study was conducted); population characteristics (sample size, context in which the study was conducted and other population characteristics); description of prognostic factors and outcomes and their definitions; and study results (measures of association or crude event rates for every candidate prognostic factor and outcome reported). Risk of bias assessment Two reviewers assessed the risk of bias of individual included studies independently and in duplicate. Discrepancies were resolved by consensus. We used the Quality in Prognosis Studies (QUIPS) tool for prognostic factor studies [11] which considers population characteristics, attrition, prognostic factor and outcome measurement and potential residual confounding. For “study confounding summary” and “statistical analysis and presentation domains”, in order to assess adequacy of the multivariable models, we considered appropriate model adjustment as based on inclusion of age, one comorbidity (e.g diabetes) and one parameter of disease severity (e.g. respiratory rate) at minimum. Data synthesis